Palisade Bio (PALI) Soars 5% Ahead of Clinical Trial Results

We recently published 10 Stocks Lighting Up Market Ahead of Christmas. Palisade Bio Inc. (NASDAQ:PALI) is one of the best performers on Wednesday.

Palisade extended its winning streak to a fourth straight day on Wednesday, jumping 5.26 percent to close at $2.20 apiece as investors loaded portfolios ahead of the results of its clinical trial for its treatment of fibrostenotic Crohn’s disease (FSCD).

The company is targeting to present the topline results of its Phase 1b study of PALI-2108 in the first quarter of 2026, with the Investigational New Drug submission expected in the first half of next year.

The first phase enrolled approximately 6 to 12 patients with FSCD, and was designed to evaluate the efficacy of PALI-2108 over a 14-day treatment period.

Results aside, the rally in Palisade Bio Inc. (NASDAQ:PALI) can also be attributed to some window-dressing activities—a practice among institutional investors where they tweak their portfolios before reporting periods, typically done quarterly and annually, by loading up on well-performing stocks and trimming those that underperform, to perform a stronger portfolio for clients.

Palisade Bio (PALI) Soars 5% Ahead of Clinical Trial Results

Year-to-date, Palisade Bio Inc.’s (NASDAQ:PALI) shares were up by 33.33 percent.

Palisade Bio Inc. (NASDAQ:PALI) is a clinical-stage biopharmaceutical company advancing a next generation of once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic diseases.

While we acknowledge the potential of PALI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

[/im-yf-promo]

While we acknowledge the risk and potential of PALI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PALI and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.